Mathias Schmidt
Director/Miembro de la Junta en JCR PHARMACEUTICALS CO., LTD. .
Cargos activos de Mathias Schmidt
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Director/Miembro de la Junta | 01/06/2020 | - |
| Corporate Officer/Principal | 01/06/2020 | - | |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Director/Miembro de la Junta | 01/10/2016 | - |
| Director Ejecutivo | - | - | |
| JCR USA, Inc. | Director Ejecutivo | - | - |
| Presidente | - | - |
Historial de carrera de Mathias Schmidt
Formación de Mathias Schmidt.
| University of Freiburg | Doctorate Degree |
| Universität Stuttgart | Graduate Degree |
Estadísticas
Internacional
| Alemania | 3 |
| Estados Unidos | 3 |
| Japón | 2 |
Operativa
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
| Corporate Officer/Principal | 1 |
Sectorial
| Consumer Services | 3 |
| Health Technology | 2 |
| Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Health Technology |
| Empresas privadas | 2 |
|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
| JCR USA, Inc. |
- Bolsa de valores
- Insiders
- Mathias Schmidt
- Experiencia
